CST, 82759S, E7820

Product Usage Information
E7820 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 991 μL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
E7820 is an anti-cancer sulfonamide that acts as an angiogenesis inhibitor, known to degrade the RNA splicing factor RBM39 (1). It is understood that patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) can exhibit mutations in RNA splicing factor genes, including , which is crucial for AML cell survival (2). By acting as a splicing factor inhibitor, E7820 encourages RBM39 proteasomal degradation, which can help suppress splicing events that may contribute to unchecked cancer cell growth (2). It is also thought that the effect E7820 has on splicing factors could potentially influence integrin expression and/or function, specifically, integrin α2 (1). Because integrins are involved in cell migration, splicing factor degradation can play a role in altering the manner in which cancer cells migrate (3). The E7820 IC value varies depending on the context in which the drug is studied but can range from 1-5 µM for splicing factor inhibition (2).